SOURCE: Auxilium Pharmaceuticals, Inc.

October 10, 2007 07:30 ET

Auxilium Pharmaceuticals to Webcast Analyst and Institutional Investor Meeting on October 17, 2007

MALVERN, PA--(Marketwire - October 10, 2007) - Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) will webcast its analyst and institutional investor meeting to be held at the Grand Hyatt Hotel, on Park Avenue at Grand Central, in New York City on Wednesday, October 17, 2007.

The event will feature a discussion of clinical data and potential future commercial opportunities for XIAFLEX™, the Company's lead pipeline candidate that is currently in phase III development for the treatment of Dupuytren's contracture and in phase II development for the treatment of Peyronie's disease. Participants from Auxilium will include Mr. Armando Anido, Chief Executive Officer and President, Mr. Jim Fickenscher, Chief Financial Officer, Mr. Roger Graham, Executive Vice President, Sales and Marketing, and Dr. Jyrki Mattila, Executive Vice President, Business Development, R&D, and Technical Operations. Speakers will include the following leading scientific experts in the treatment of Dupuytren's contracture and Peyronie's disease:

--  Lawrence Hurst, M.D., Professor and Chair, Chief of Hand Surgery,
    Department of Orthopaedics of the Health Science Center, State University
    of New York at Stony Brook
--  Gerald H. Jordan, M.D., F.A.C.S., F.A.A.P., Professor, Department of
    Urology, Eastern Virginia Medical School Director, Devine Center for
    Genitourinary Reconstructive Surgery, Sentara Norfolk General Hospital
    

The event will be held from 11:30 a.m. to 3:30 p.m. Eastern Time. To access the live web cast for the presentation, which will begin at 12:00 p.m. Eastern Time, please log on to the Company's web site at www.auxilium.com approximately 15 minutes prior to the presentation. The web cast will also be archived and available on the Company's web site approximately one hour after completion of the live web cast and will remain available for approximately 90 days after the event.

About Auxilium

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing to urologists, endocrinologists, orthopedists and select primary care physicians. Auxilium markets Testim® 1%, a topical testosterone gel, for the treatment of hypogonadism, through its approximately 190-person sales and marketing team. Auxilium has four projects in clinical development. XIAFLEX™ (clostridial collagenase for injection), formerly referred to as AA4500, is in phase III of development for the treatment of Dupuytren's contracture and is in phase II of development for the treatment of Peyronie's disease and Frozen Shoulder syndrome (Adhesive Capsulitis). Auxilium's transmucosal film product candidate for the treatment of overactive bladder (AA4010) is in phase I of development. The Company is currently seeking a partner to further develop this product candidate. Auxilium has two pain products using its transmucosal film delivery system in pre-clinical development. Auxilium has rights to six additional pain products and products for hormone replacement and urologic disease using its transmucosal film delivery system. Auxilium also has options to all indications using XIAFLEX for non-topical formulations. For additional information, visit http://www.auxilium.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the future potential commercial opportunities for XIAFLEX, the Company's intention to webcast the Analyst and Institutional Investor Meeting and the Company's products in development for Dupuytren's contracture, Peyronie's disease, Frozen Shoulder syndrome, overactive bladder, pain, hormone replacement and urologic disease. All statements other than statements of historical facts contained in this release, including but not limited to, statements regarding future expectations, plans and prospects for the Company, statements regarding forward-looking financial information and other statements containing the words "believe," "may," "could," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," and similar expressions, as they relate to the Company, constitute forward-looking statements. Actual results may differ materially from those reflected in these forward-looking statements due to various factors, including general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2006 and in the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2007 under the heading "Risk Factors," which are on file with the Securities and Exchange Commission (the "SEC") and may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov or by means of the Company's home page on the Internet at http://www.auxilium.com under the heading "Investor Relations -- SEC Filings." There may be additional risks that the Company does not presently know or that the Company currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements.

In addition, forward-looking statements provide the Company's expectations, plans or forecasts of future events and views as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company's assessments to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's assessments as of any date subsequent to the date of this release.

Contact Information

  • For More Information, Contact:

    James E. Fickenscher
    Chief Financial Officer
    Auxilium Pharmaceuticals, Inc.
    (484) 321-5900
    Email Contact

    Gregory Gin
    Lazar Partners, Ltd.
    (212) 867-1762
    Email Contact